Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

On October 17, 2019 Arvinas Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, reported it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit (Press release, Arvinas, OCT 17, 2019, View Source [SID1234542328]). In one of these sessions, Ian Taylor, Ph.D., Chief Scientific Officer at Arvinas, will share an update on the company’s PROTAC protein degrader platform, including initial safety, tolerability, and pharmacokinetic data from Arvinas’ ongoing Phase 1 clinical trials of ARV-110 and ARV-471.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Taylor’s presentation is October 23 and is one of three that Arvinas will participate in at the conference, which is being held October 22-24 at the Hilton Boston Logan Airport in Boston, MA. On October 24, Angela Cacace, Ph.D., VP of Neuroscience and Platform Biology at Arvinas, will share recent data from Arvinas’ preclinical neurodegeneration programs targeting tau and alpha-synuclein. Also, on October 24, Randy Teel, Ph.D., VP of Corporate Development, will participate in a panel discussion on the field of targeted protein degradation.

Arvinas Presentations at the 2nd Targeted Protein Degradation Summit

Moving PROTAC Protein Degraders from the Laboratory to the Clinic
° Presenter: Ian Taylor, Ph.D., CSO
° Date and Time: October 23 – 11:30 AM
Keynote Plenary: Accelerating Emerging Protein Degraders into the Clinic: Industry Leaders Panel Discussion
° Panelist: Randy Teel, Ph.D., VP, Corporate Development
° Date and Time: October 24 – 9:30 AM
Discovery of Brain Penetrant PROTACDegrader Molecules that Target Pathologic Tau Protein Species
° Presenter: Angela Cacace, Ph.D., VP, Neuroscience and Platform Biology
° Date and Time: October 24 – 11:30 AM